GIP
TEVA icon

Greatmark Investment Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Greatmark Investment Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-900
Closed -$16K – 120
2017
Q3 		$16K Hold
900
– – 0.01% 114
2017
Q2 		$30K Buy
+900
New +$27.9K 0.01% 106

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Greatmark Investment Partners's TEVA Position: Q3 2021 in Review

Greatmark Investment Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2021, closing a stake of 19,601 shares — an estimated $194K sold.

Greatmark Investment Partners first reported a position in TEVA in Q2 2013 and held it in 33 quarters. The position peaked at $7.45M in Q4 2015. 429 funds tracked by Wall St. Rank hold TEVA as of Q3 2021.

  • Greatmark Investment Partners reported no remaining Teva Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Greatmark Investment Partners sold 19,601 Teva Pharmaceuticals shares in Q3 2021, an estimated $194K.
  • Greatmark Investment Partners first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Greatmark Investment Partners's Teva Pharmaceuticals position peaked at $7.45M in Q4 2015.
  • 429 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2021.

Based on Greatmark Investment Partners's 13F filing for Q3 2021, filed 2 Nov 2021.